News & Updates

Show Multimedia Only

Durvalumab plus chemo delivers sustained survival benefits in advanced BTC

13 Nov 2025 by

A 3-year update from the phase III TOPAZ-1 study has shown sustained survival benefit and manageable safety with durvalumab plus gemcitabine and cisplatin (GemCis) relative to placebo among patients with advanced biliary tract cancer (BTC).

Durvalumab plus chemo delivers sustained survival benefits in advanced BTC

13 Nov 2025

Rivaroxaban may prevent PHT-related complications in cirrhosis

13 Nov 2025

Treatment with rivaroxaban appears to improve portal hypertension (PHT)-related complications without increasing the risk of major bleeding in patients with cirrhosis and moderate liver dysfunction, a study has shown.

Rivaroxaban may prevent PHT-related complications in cirrhosis

13 Nov 2025

Sodium bicarbonate of no help in metabolic acidemia, acute kidney injury

13 Nov 2025

Intravenous treatment with sodium bicarbonate does not appear to confer survival benefits in patients with severe metabolic acidemia and moderate to severe acute kidney injury, as shown in a study.

Sodium bicarbonate of no help in metabolic acidemia, acute kidney injury

13 Nov 2025

Rescue combo therapy outshines albuterol alone for mild asthma

12 Nov 2025 by

As-needed treatment with the combination of albuterol plus budesonide works better than albuterol alone for preventing severe exacerbations in patients with uncontrolled mild asthma, according to the phase IIIb BATURA trial.

Rescue combo therapy outshines albuterol alone for mild asthma

12 Nov 2025

Short-course nafithromycin noninferior to 7-day moxifloxacin regimen for pneumonia

11 Nov 2025 by

A 3-day course of oral nafithromycin is equally efficacious as the 7-day course of oral moxifloxacin for the treatment of community-acquired bacterial pneumonia (CABP) in adults, as shown in a phase III study.

Short-course nafithromycin noninferior to 7-day moxifloxacin regimen for pneumonia

11 Nov 2025

Chemo-free treatment combination prolongs survival in previously treated mCRC

10 Nov 2025 by

Treatment with the multitargeted tyrosine-kinase inhibitor zanzalintinib, when combined with atezolizumab, confers an overall survival benefit in previously treated metastatic colorectal cancer (mCRC), according to the phase III STELLAR-303 trial.

Chemo-free treatment combination prolongs survival in previously treated mCRC

10 Nov 2025

Oral nitrates tied to lower risk of glaucoma in patients with chronic ischaemic heart disease

10 Nov 2025

In patients with chronic ischaemic heart disease (IHD), the use of oral nitrates helps lower the risk of open-angle glaucoma (OAG) and primary open-angle glaucoma (POAG), according to a retrospective study.

Oral nitrates tied to lower risk of glaucoma in patients with chronic ischaemic heart disease

10 Nov 2025

HER2-expressing urothelial cancer gets survival boost with disitamab vedotin–toripalimab combo

09 Nov 2025 by

In the frontline treatment of patients with HER2-expressing locally advanced or metastatic urothelial cancer, the combination of disitamab vedotin plus toripalimab yields a clinically meaningful and significant increase in survival compared with chemotherapy, as shown in the phase III RC48-C016 trial.

HER2-expressing urothelial cancer gets survival boost with disitamab vedotin–toripalimab combo

09 Nov 2025

Bexicaserin shows promise in developmental and epileptic encephalopathies

08 Nov 2025

In the treatment of patients with developmental and epileptic encephalopathies (DEEs), the selective serotonin 5-HT2C receptor agonist bexicaserin is well tolerated and appears to reduce the frequency of countable motor seizures, according to a phase Ib/IIa study.

Bexicaserin shows promise in developmental and epileptic encephalopathies

08 Nov 2025

Liraglutide promotes weight loss after suboptimal response to bariatric surgery

07 Nov 2025 by

For patients who are struggling to lose weight after metabolic bariatric surgery, treatment with liraglutide boosts weight-loss outcomes and helps avoid conversion surgery, as shown in a randomized clinical trial.

Liraglutide promotes weight loss after suboptimal response to bariatric surgery

07 Nov 2025

News & Updates

Filter by Specialty:

Specialty:

Durvalumab plus chemo delivers sustained survival benefits in advanced BTC

Durvalumab plus chemo delivers sustained survival benefits in advanced BTC

Rivaroxaban may prevent PHT-related complications in cirrhosis

Rivaroxaban may prevent PHT-related complications in cirrhosis

Sodium bicarbonate of no help in metabolic acidemia, acute kidney injury

Sodium bicarbonate of no help in metabolic acidemia, acute kidney injury

Rescue combo therapy outshines albuterol alone for mild asthma

Rescue combo therapy outshines albuterol alone for mild asthma

Short-course nafithromycin noninferior to 7-day moxifloxacin regimen for pneumonia

Short-course nafithromycin noninferior to 7-day moxifloxacin regimen for pneumonia

Chemo-free treatment combination prolongs survival in previously treated mCRC

Chemo-free treatment combination prolongs survival in previously treated mCRC

Oral nitrates tied to lower risk of glaucoma in patients with chronic ischaemic heart disease

Oral nitrates tied to lower risk of glaucoma in patients with chronic ischaemic heart disease

HER2-expressing urothelial cancer gets survival boost with disitamab vedotin–toripalimab combo

HER2-expressing urothelial cancer gets survival boost with disitamab vedotin–toripalimab combo

Bexicaserin shows promise in developmental and epileptic encephalopathies

Bexicaserin shows promise in developmental and epileptic encephalopathies

Liraglutide promotes weight loss after suboptimal response to bariatric surgery

Liraglutide promotes weight loss after suboptimal response to bariatric surgery